Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin (factor IIa). Some are in clinical use, …

Direct thrombin inhibitors provide another option for people who have blood clots or need to prevent them. These medications have predictable results and don’t require frequent blood …

2005年9月8日 · Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to thrombin and block its interaction with its substrates. Four parenteral DTIs have …

This topic review discusses practical aspects of the use of direct thrombin inhibitors (oral and parenteral) and oral direct factor Xa inhibitors, along with a brief mention of other …

Currently, four parenteral direct inhibitors of thrombin activity are FDA-approved in North America: lepirudin, desirudin, bivalirudin and argatroban. Of the new oral DTIs, dabigatran etexilate is …

2011年8月1日 · Direct thrombin inhibitors (DTIs) are a class of anticoagulants that act by directly inhibiting thrombin to delay clotting and are typically used during HIT and in acute coronary …

Thrombin inhibitors inactivate free thrombin and also the thrombin that is bound to fibrin. Thrombin inhibitors are used to prevent arterial and venous thrombosis. They can also be used to …

Several direct thrombin inhibitors (DTIs) have been approved for clinical use in the prevention of thrombosis, for example desirudin.

Anticoagulants are medications used to prevent the formation of thrombi, or blood clots, and they’re used to prevent or treat thromboembolic events, such as deep vein thrombosis, …

2012年5月1日 · We review three direct thrombin inhibitors approved for routine clinical use (bivalirudin, argatroban, and dabigatran etexilate), and the results of the associated major …